D-mannose augments targeted radioligand-immunotherapy of prostate cancer by enhancing radiosensitivity and reshaping immune microenvironment [0.03%]
D-木糖通过增强放射敏感性及重塑免疫微环境增效靶向放射配体-免疫治疗前列腺癌
Lei Tao,Bin Xu,Juan Sun et al.
Lei Tao et al.
Targeted radioligand therapy (TRT) is an emerging therapeutic modality for advanced tumors like metastatic castration-resistant prostate cancer. The patients bare, however, varying degrees of resistance to TRT, which would greatly lessen the treatment efficacy and response rate.
The Influence of Radioligand Therapy on Immunogenicity Against SARS-CoV-2-A Retrospective Single-Arm Cohort Study of Metastatic Prostate Cancer Patients Receiving PSMA Radioligand Therapy [0.03%]
放射配体治疗对SARS-CoV-2免疫原性影响的单臂队列研究：接受前列腺癌PSMA放射配体治疗的转移性前列腺癌患者的回顾性研究
Carsten S Kramer,Aleksandr Eismant,Aditi Mishra et al.
Carsten S Kramer et al.
While many chemotherapies can severely diminish the effect of vaccines against SARS-CoV-2, the effect of radioligand therapy has not yet been studied so far....Methods: In our database, 64 patient records of patients with metastatic castration-resistant prostate cancer that were treated with PSMA-directed radioligand therapy (PRLT) were randomly selected and checked for specific information (vaccination status, past corona virus disease 2019 (COVID-19) infections
In Vitro and In Vivo Study of Novel PSMA-Targeted Radioligands: Enhancing Tumor Uptake and Therapeutic Efficacy through Zwitterionization and Albumin-Binding Strategies [0.03%]
新型PSMA靶向放射配体的体内外研究：通过两性离子化和白蛋白结合策略增强肿瘤摄取和治疗疗效
Yang Liu,Haiyang Li,Han Zhou et al.
Yang Liu et al.
Prostate-specific membrane antigen (PSMA) targeted radioligand therapy (TRT) for metastatic castration-resistant prostate cancer has demonstrated significant potential.
PSMA targeted Therapy: From molecular mechanisms to clinical breakthroughs in castration-resistant prostate cancer [0.03%]
靶向PSMA的治疗：去势抵抗性前列腺癌分子机制与临床突破之间的联系
Licheng Wang,Change Lu,Xin&#x;an Wang et al.
Licheng Wang et al.
We critically examine the latest advancements in PSMA-targeted treatment strategies, including radioligand therapy (e.g., 177Lu-PSMA-617), antibody-drug conjugates, bispecific T-cell engagers, and small-molecule PSMA inhibitors.
Availability and use of PET in patients with brain tumours - a European Organisation for Research and Treatment of Cancer - Brain Tumour Group (EORTC-BTG) survey [0.03%]
欧洲癌症研究与治疗组织-脑肿瘤组(EORTC-BTG)关于脑肿瘤患者中PET的可用性及应用情况的调查
Maximilian J Mair,Philipp Lohmann,Norbert Galldiks et al.
Maximilian J Mair et al.
Somatostatin receptor (SSTR) PET was performed at 50/68 sites (73.5%, 6 n.r.), mainly in meningioma (48/49, 98.0%), for patient selection before radioligand therapy (41/49, 83.7%) and for radiotherapy target volume definition (33/49, 67.3%).
Predictive factors for persistent thrombocytopenia after peptide receptor radioligand therapy in enteropancreatic neuroendocrine tumors [0.03%]
肽受体放射配体治疗肠胰神经内分泌肿瘤后持久血小板减少的预测因素
Romain Ferrara,Christophe Zemmour,Thibaut Reichert et al.
Romain Ferrara et al.
Introduction: Peptide receptor radionuclide therapy (PRRT) is an effective and well-tolerated treatment for advanced neuroendocrine tumors (NETs). However, persistent thrombocytopenia (PT) has been reported and may compro...
Safety and Efficacy of Lutetium-177 PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer with Diffuse Bone Metastases (Asian Population Study) [0.03%]
Lu-177PSMA核素治疗广泛骨转移的转移性去势抵抗性前列腺癌的疗效和安全性（亚洲人群研究）
Cherie Wei Qi Ng,Wei Ming Chua,Winnie Wing-Chuen Lam et al.
Cherie Wei Qi Ng et al.
This study evaluates the safety and efficacy of [177Lu]Lu-PSMA radioligand therapy (RLT) in this high-risk group within an Asian population.
Newly emerging tyrosine kinase inhibitors for the treatment of neuroendocrine neoplasms [0.03%]
新兴的酪氨酸激酶抑制剂在神经内分泌肿瘤治疗中的应用
Nicola Fazio,Anna La Salvia
Nicola Fazio
Introduction: In the era of precision medicine, a molecularly targeted therapeutical approach is still missing in the field of neuroendocrine neoplasms (NENs) other than for radioligand therapy (RLT).
Based on small molecules: development and application of fibroblast activation protein inhibitors radiopharmaceutical in tumor precision therapy [0.03%]
基于小分子的成纤维细胞活化蛋白放射性药物的研发及应用促进肿瘤精准治疗
Yihui Luo,Haitian Fu,Chunjing Yu
Yihui Luo
This review also delineates the progress on clinical FAPI as a radioisotope delivery vehicle for the targeted radioligand therapy of tumors and introduces the latest combination therapy involving FAPI radiopharmaceutical for tumor treatment....The findings provide novel therapeutic insights into the targeted radioligand therapy of tumors.
The Development of Al18F-NOTA-FAP-2286 as an FAP-Targeted PET Tracer and the Translational Application in the Diagnosis of Acquired Drug Resistance in Progressive Prostate Cancer [0.03%]
以Al18F-NOTA-FAP-2286作为FAP靶向PET示踪剂的发展及其在药物耐药的转移性前列腺癌中的诊断应用研究
Xia Du,Yu Zhang,Yao Jia et al.
Xia Du et al.
Objectives: Tumor heterogeneity and acquired resistance to prostate-specific membrane antigen (PSMA) radioligand therapy (PRLT) pose significant challenges to PSMA PET-based diagnosis.
耗时 0.13436 秒，为您在
48229835
条记录里面共找到 724 篇文章 [XML]